Fate Therapeutics presented data on its off-the-shelf CAR T-cell therapies FT819 and FT839 at the 2026 European Congress of Rheumatology. FT819 showed rapid, sustained clinical improvement in 21 lupus patients with a favorable safety profile and enabled outpatient treatment, highlighting its potential for broad accessibility. FT839 demonstrated preclinical efficacy in targeting immune cells in rheumatoid arthritis without the need for conditioning chemotherapy. The company plans to advance FT819 into a Phase 2 trial for lupus nephritis and continue developing FT839 for autoimmune diseases, aiming to transform treatment options for serious autoimmune conditions.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
